ICCC (ImmuCell) Cyclically Adjusted Book per Share: $4.61 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICCC ImmuCell Corp ICCC
54 GF Score
Price $10.13
GF Value $6.91
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Cyclically Adjusted Book per Share?

ImmuCell ICCC +4.00% 54 Cyclically Adjusted Book per Share is $4.61 as of Jun. 2026. GuruFocus rates ICCC with a GF Score™ of 54/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

ImmuCell's adjusted book value per share for the three months ended in Jun. 2026 was $3.455. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.61 for the trailing ten years ended in Jun. 2026.

During the past 12 months, ImmuCell's average Cyclically Adjusted Book Growth Rate was -0.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 0.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 3.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of ImmuCell was 14.50% per year. The lowest was 0.00% per year. And the median was 4.20% per year.

As of today (2026-08-20), ImmuCell's current stock price is $10.13. ImmuCell's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $4.61. ImmuCell's Cyclically Adjusted PB Ratio of today is 2.20.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ImmuCell was 3.08. The lowest was 0.77. And the median was 1.60.


ImmuCell  (NAS:ICCC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ImmuCell's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.13/4.61
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ImmuCell was 3.08. The lowest was 0.77. And the median was 1.60.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


ImmuCell Cyclically Adjusted Book per Share Related Terms


ImmuCell Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for ImmuCell's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell Cyclically Adjusted Book per Share Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.18 4.47 4.55 4.58 4.57

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.63 4.63 4.57 4.61 4.61

ICCC vs COYA, ENTX, BDTX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, ImmuCell's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ImmuCell's Cyclically Adjusted PB Ratio falls into.


ICCC
54GF Score
ImmuCell Corp ICCC
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ImmuCell's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.455/333.9520*333.9520
=3.455

Current CPI (Jun. 2026) = 333.9520.

ImmuCell Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.918 241.428 5.420
201612 4.069 241.432 5.628
201703 4.201 243.801 5.754
201706 4.166 244.955 5.680
201709 4.148 246.819 5.612
201712 4.309 246.524 5.837
201803 4.287 249.554 5.737
201806 4.160 251.989 5.513
201809 4.134 252.439 5.469
201812 3.904 251.233 5.189
201903 4.195 254.202 5.511
201906 4.112 256.143 5.361
201909 4.048 256.759 5.265
201912 4.019 256.974 5.223
202003 4.019 258.115 5.200
202006 3.921 257.797 5.079
202009 3.885 260.280 4.985
202012 3.916 260.474 5.021
202103 3.860 264.877 4.867
202106 4.168 271.696 5.123
202109 4.193 274.310 5.105
202112 4.208 278.802 5.040
202203 4.310 287.504 5.006
202206 4.231 296.311 4.768
202209 4.128 296.808 4.645
202212 3.922 296.797 4.413
202303 3.635 301.836 4.022
202306 3.467 305.109 3.795
202309 3.358 307.789 3.643
202312 3.224 306.746 3.510
202403 3.178 312.332 3.398
202406 2.994 314.175 3.182
202409 2.990 315.301 3.167
202412 3.065 315.605 3.243
202503 3.228 319.799 3.371
202506 3.303 322.561 3.420
202509 3.294 324.800 3.387
202512 2.991 324.054 3.082
202603 3.220 330.213 3.256
202606 3.455 333.952 3.455

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $4.61 mean?
ImmuCell (ICCC) has a Cyclically Adjusted Book per Share of $4.61 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on ImmuCell and its competitors.
Is ImmuCell's Cyclically Adjusted Book per Share too high?
ImmuCell's current Cyclically Adjusted Book per Share is $4.61. Overall, ImmuCell has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Cyclically Adjusted Book per Share compare to COYA and ENTX?
ImmuCell's Cyclically Adjusted Book per Share of $4.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on ImmuCell and its competitors. ImmuCell's current Cyclically Adjusted Book per Share is $4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.13 — trading 46.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is $4.61. ImmuCell's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For ImmuCell (ICCC), the current Cyclically Adjusted Book per Share is $4.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (ICCC) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of $10.13 is trading 46.6% above its estimated GF Value™ of $6.91. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for ICCC:

  • Cyclically Adjusted Book per Share: $4.61
  • GF Value™: $6.91 vs. price of $10.13 (46.6% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ImmuCell Business Description

Other Exchanges IUL:Germany
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
54GF Score

Get the complete analysis for ICCC

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.13
Price
$6.91
GF Value